5-Iod-2',5'-dideoxyuridin | 58510-67-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 2 '，5'-二脱氧核苷
• 英文名称: 5-Iod-2',5'-dideoxyuridin
• 英文别名: 2',5'-Dideoxy-5-iodouridine；1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]-5-iodopyrimidine-2,4-dione
• CAS: 58510-67-1
• 化学式: C₉H₁₁IN₂O₄
• 分子量: 338.102
• InChiKey: GUVUYJRNOZXTJV-PRMYIZFSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Stabilized siRNAs as transfection controls and silencing reagents
  申请人：Leake Devin

  公开号：US20070269889A1

  公开（公告）日：2007-11-22

  RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5′ terminal sense nucleotides with 2′-O-alkyl groups and a label on the first 5′ terminal sense nucleotide, in conjunction with at least one additional 2′-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2′ fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5′ terminal antisense nucleotide; or (ii) a first and second 5′ terminal antisense nucleotide with 2′-O-alkyl modifications and at least one additional 2′-O-alkyl pyrimidine modified antisense nucleotide.

  提供了包括siRNA分子和相关的控制、可追踪性和稳定性修饰的分子。这些分子作为转染控制试剂特别有优势。这些分子包括第一和第二个5'端感受核苷酸，具有2'-O-烷基基团和第一个5'端感受核苷酸上的标记，与至少一个额外的2'-O-烷基嘧啶修饰的感受核苷酸一起，以及：（i）至少一个2'-氟修饰的嘧啶反义核苷酸和一个磷酸化的第一个5'端反义核苷酸；或者（ii）第一和第二个5'端反义核苷酸具有2'-O-烷基修饰和至少一个额外的2'-O-烷基嘧啶修饰的反义核苷酸。
• STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
  申请人：Leake Devin

  公开号：US20090280567A1

  公开（公告）日：2009-11-12

  RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5′ terminal sense nucleotides with 2′-O-alkyl groups and a label on the first 5′ terminal sense nucleotide, in conjunction with at least one additional 2′-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2′ fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5′ terminal antisense nucleotide; or (ii) a first and second 5′ terminal antisense nucleotide with 2′-O-alkyl modifications and at least one additional 2′-O-alkyl pyrimidine modified antisense nucleotide.

  提供了RNA分子，包括siRNA分子和相关的控制、可追踪性和具有特定稳定性修饰的exaequo剂。这些分子作为转染控制试剂特别有优势。这些分子包括第一和第二个5'端的感知核苷酸，具有2'-O-烷基基团和第一5'端的标签，以及至少一个附加的2'-O-烷基嘧啶修饰感知核苷酸，以及：(i)至少一个2'-氟修饰的嘧啶反义核苷酸和一个磷酸化的第一5'端反义核苷酸；或者(ii)第一和第二个5'端反义核苷酸具有2'-O-烷基修饰和至少一个附加的2'-O-烷基嘧啶修饰反义核苷酸。
• Stabilized RNAS as transfection controls and silencing reagents
  申请人：Dharmacon, Inc.

  公开号：EP2123759A2

  公开（公告）日：2009-11-25

  RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include an RNA duplex comprising: (a) a sense strand, wherein said sense strand comprises (i) a first 5' terminal sense nucleotide and a second 5' terminal sense nucleotide, wherein said first 5' terminal sense nucleotide comprises a first 2'-O-alkyl sense modification and said second 5' terminal sense nucleotide comprises a second 2'-O-alkyl sense modification; (ii) at least one 2'-O-alkyl pyrimidine modified sense nucleotide, wherein said at least one 2'-O-alkyl pyrimidine modified sense nucleotide is a nucleotide other than said first 5' terminal sense nucleotide or said second 5' terminal sense nucleotide; and (b) an antisense strand, wherein said antisense strand comprises (i) a first 5' terminal antisense nucleotide and a second 5' terminal antisense nucleotide, wherein said first 5' terminal antisense nucleotide comprises a first 2'-O-alkyl antisense modification and said second 5' terminal antisense nucleotide comprises a second 2'-O-alkyl antisense modification; and (ii) at least one 2'-O-alkyl pyrimidine modified antisense nucleotide, wherein said at least one 2'-O-alkyl modified antisense nucleotide is a nucleotide other than said first 5' terminal antisense nucleotide or said second 5' terminal antisense nucleotide, wherein the sense strand and antisense strand are capable of forming a duplex of between 16 and 50 base pairs.

  提供了包括 siRNA 分子在内的 RNA 分子以及具有特定稳定性修饰的相关控制、可追踪性和 exaequo 剂。这些分子作为转染控制试剂尤其具有优势。这些分子包括一个 RNA 双链，其中包括 (a) 有义链，其中所述有义链包括 (i) 第一个 5'末端有义核苷酸和第二个 5'末端有义核苷酸，其中所述第一个 5'末端有义核苷酸包括第一个 2'-O-烷基有义修饰，所述第二个 5'末端有义核苷酸包括第二个 2'-O-烷基有义修饰； (ii) 至少一个 2'-O-烷基嘧啶修饰的感应核苷酸，其中所述至少一个 2'-O-烷基嘧啶修饰的感应核苷酸是除所述第一 5'末端感应核苷酸或所述第二 5'末端感应核苷酸之外的核苷酸；以及 (b) 反义链，其中所述反义链包括 (i) 第一 5'末端反义核苷酸和第二 5'末端反义核苷酸，其中所述第一 5'末端反义核苷酸包括第一 2'-O-烷基反义修饰，所述第二 5'末端反义核苷酸包括第二 2'-O-烷基反义修饰；以及 (ii) 至少一个 2'-O-烷基嘧啶修饰的反义核苷酸，其中所述至少一个 2'-O-烷基修饰的反义核苷酸是所述第一 5'末端反义核苷酸或所述第二 5'末端反义核苷酸以外的核苷酸、 其中，有义链和反义链能够形成 16 至 50 个碱基对的双链。
• Electrokinetic delivery of medicaments
  申请人：BIOPHORETIC THERAPEUTIC SYSTEMS, LLC

  公开号：US20030018295A1

  公开（公告）日：2003-01-23

  An electrokinetic delivery or diagnostic device for personal use and self-administration of a medicament to a treatment site is provided. The device includes a housing containing a power supply, a first active electrode and a ground tactile electrode. An applicator includes a pad for containing medicament for overlying the first electrode of the device. The medicament may be applied by the user to the pad, contained within the pad or contained in rupturable capsules within the pad, together with a hydrogel if necessary for imparting electrical conductivity whereby, upon application of the applicator to the treatment site, the medicament is electrokinetically transported into the treatment site. In another form, the applicator is self-contained, having a power supply, a first electrode overlying a pad and a ground electrode from the opposite side from the pad whereby the individual presses the pad against the treatment site to complete the electrical circuit and electrokinetically drive the medicament into the treatment site.

  本文提供了一种个人使用的电动给药或诊断装置，可将药物自行给药到治疗部位。该装置包括一个外壳，内含一个电源、一个第一有源电极和一个接地触觉电极。涂抹器包括一个垫子，用于在设备的第一电极上覆盖药剂。用户可将药剂涂抹在垫子上，或将药剂装在垫子内，或将药剂装在垫子内的可破裂胶囊中，必要时还可加上水凝胶，以赋予药剂导电性，从而在将涂抹器涂抹到治疗部位时，将药剂以电动方式输送到治疗部位。在另一种形式中，涂抹器是独立的，有一个电源、一个覆盖在垫子上的第一电极和一个与垫子相对的接地电极。
• STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
  申请人：Dharmacon, Inc.

  公开号：EP1718747A2

  公开（公告）日：2006-11-08